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Abstract
Background: Pneumonia is the leading cause of child mortality under five years of age worldwide. For pneumonia
with chest indrawing in children aged 3–59 months, injectable penicillin and hospitalization was the recommended
treatment. This increased the health care cost and exposure to nosocomial infections. We compared the clinical
and cost outcomes of a seven day treatment with oral amoxicillin with the first 48 h of treatment given in the
hospital (hospital group) or at home (home group).
Methods: We conducted an open-label, multi-center, two-arm randomized clinical trial at six tertiary hospitals in
India. Children aged 3 to 59 months with chest indrawing pneumonia were randomized to home or hospital
group. Clinical outcomes, treatment adherence, and patient safety were monitored through home visits on day 3, 5,
8, and 14 with an additional visit for the home group at 24 h. Clinical outcomes included treatment failure rates up
to 7 days (primary outcome) and between 8–14 days (secondary outcome) using the intention to treat and per
protocol analyses. Cost outcomes included direct medical, direct non-medical and indirect costs for a random 17 %
subsample using the micro-costing technique.
Results: 1118 children were enrolled and randomized to home (n = 554) or hospital group (n = 564). Both groups
had similar baseline characteristics. Overall treatment failure rate was 11.5 % (per protocol analysis). The hospital
group was significantly more likely to fail treatment than the home group in the intention to treat analysis.
Predictors with increased risk of treatment failure at any time were age 3–11 months, receiving antibiotics within
48 h prior to enrolment and use of high polluting fuel. Death rates at 7 or 14 days did not differ significantly.
(Difference −0.0 %; 95 % CI −0.5 to 0.5). The median total treatment cost was Rs. 399 for the home group versus Rs.
602 for the hospital group (p < 0.001), for the same effect of 5 % failure rate at the end of 7 days of treatment in
the random subsample.
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Conclusions: Home based oral amoxicillin treatment was equivalent to hospital treatment for first 48 h in selected
children of chest indrawing pneumonia and was cheaper. Consistent with the recent WHO simplified guidelines,
management with home based oral amoxicillin for select children with only fast breathing and chest-indrawing can
be a cost effective intervention.
Trial Registration: ClinicalTrials.gov NCT01386840, registered 25th June 2011 and the Indian Council of Medical
Research REFCTRI/2010/000629.
Keywords: Severe pneumonia, Lower chest indrawing, Hospitalization, Oral amoxicillin, Cost effective, Randomized
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Background
Pneumonia is the single largest killer of children under
the age of five worldwide [1]. The disease kills over two
million children under the age of five every year— nearly
one fourth (400,000) of these deaths occur in India alone
[2]. About half of pneumonia cases in India are caused
by bacteria and could be treated with antibiotics. How-
ever, only 13 % of Indian children under the age of five
with suspected pneumonia receive antibiotics [3].
The 2008 WHO guidelines for treatment of non-
severe pneumonia (cough, fever and fast breathing)
recommend health workers to provide oral antibi-
otics for three days at home but urgent referral for
hospitalization for parenteral (injectable) antibiotics
and other supportive therapy after administration of
first dose of antibiotics, if the child has severe pneu-
monia (cough, fever, fast breathing and lower chest
indrawing) or very severe disease (pneumonia with
the presence of WHO defined danger signs) [4].
Often inability to access a referral facility deprives
these children from getting appropriate care. For
many families, seeking treatment for their children
at a health care facility is often logistically and fi-
nancially burdensome thus denying them early ad-
ministration of antibiotics within 48 h that can
potentially improve their outcomes. Additionally
transport to a distant facility can entail serious de-
lays in effective treatment. Many children with se-
vere pneumonia referred for admission to a hospital
could die in transit or reach too sick to be saved [5].
In addition, when hospitalized, the children with se-
vere pneumonia are vulnerable to nosocomial infec-
tions in crowded hospital wards and are also at risk
of needle-borne infections due to parenteral therapy.
Two important studies have addressed such barriers
to the recommended treatment of severe pneumonia.
The first study was intended to determine whether
oral antibiotics are equivalent to injectable antibi-
otics when both are given in the hospital. This was
an open label equivalency study called APPIS
(Amoxicillin Penicillin Pneumonia International
Study), which was a large multicentre randomized
controlled trial comparing injectable penicillin versus
oral amoxicillin given for 7 days to children in the
hospital [6]. The second study was called “NO-
SHOTS” (New Outpatient Short-Course Home Oral
Therapy for Severe Pneumonia Study) and was a
randomized, open-label equivalency trial done at
seven study sites in Pakistan and compared initial
hospitalization and parenteral ampicillin for 48 h
followed by 3 days of oral amoxicillin at home, to
5 days of home-based treatment with oral amoxicil-
lin [7]. NO-SHOTS showed that home treatment
with high-dose oral amoxicillin is equivalent to hos-
pital based treatment with parenteral ampicillin in
selected children aged 3–59 months with WHO de-
fined severe pneumonia [7]. Later, another study- the
MASS study (Multicenter Amoxicillin Severe pneu-
monia Study) showed that clinical treatment failure
and adverse event rates among children with severe
pneumonia treated at home with oral amoxicillin did
not substantially differ across geographic areas
(Bangladesh, Ghana, Vietnam and Egypt) and hence
home-based therapy of severe pneumonia could pos-
sibly be applied to a wide variety of settings [8].
Thus oral amoxicillin at home has proven clinically
efficacious in various settings across the world for
treatment of selected children with WHO defined
severe pneumonia. The Lancet Series on Childhood
Pneumonia and Diarrhoea has reported that case
management is one of the three most effective inter-
ventions to reduce pneumonia deaths in children but
also noted that the cost effectiveness of these inter-
ventions in national health systems needs urgent as-
sessment [9]. So the cost savings or cost-
effectiveness of home-based oral antibiotic treatment
for WHO defined severe pneumonia in childhood
would be important to inform public policy and has
not been previously evaluated.
Therefore our objective was to assess the efficacy and
cost-effectiveness of a 7-day home-based course of oral
amoxicillin as compared to oral amoxicillin administered
for the first 48 h in the hospital followed by 5 days of
home-administration.
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Methods
We conducted an open labelled multi-center prospective
two-arm randomized clinical trial at 6 referral hospitals
in India (Chandigarh, Chennai, Nagpur, Pune, Sewagram
and Aligarh) to evaluate the difference of rates of treat-
ment failures of a 7-day course of oral amoxicillin when
administered at home as compared to a 7-day course of
oral amoxicillin administered for the first 48 h in the
hospital followed by 5 days of home-administration to
treat WHO defined severe pneumonia in children aged
3–59 months. In addition to the clinical outcomes, the
costs of treating severe pneumonia, the differences in
costs of treatment in the two study groups and the cost-
effectiveness of the two alternative treatment strategy
was also assessed in this trial.
The study was approved by the institutional ethics
committees of: Indira Gandhi Government Medical Col-
lege, Nagpur; Post Graduate Institute of Medical Sci-
ences, Chandigarh; Government General Hospital,
Chennai; B.J. Medical College, Pune; Mahatma Gandhi
Institute of Medical Sciences, Sevagram, Wardha; Jawa-
harlal Nehru Medical College, Aligarh; the Research Eth-
ics Review Committee, World Health Organization; and
the INCLEN Institutional Review Board through the
India Clinical Epidemiology Network (IndiaCLEN, dated
18th Nov 2006).
Eligibility
Children aged 3–59 months with cough/difficulty in
breathing of less than 2 weeks duration, lower chest
indrawing (LCI), unresponsive to nebulisation, who did
not have any of the exclusion criteria (Table 1) and
whose parents gave a written informed consent for their
participation were enrolled in the study by trained re-
search staff. All included children were administered the
first dose of amoxicillin, sent for chest radiology and
then reassessed after radiology. Children were random-
ized to either treatment arms if there was no clinical de-
terioration or radiographic signs of consolidation,
effusion or pneumothorax (using the the WHO manual
for standardization of interpretation of chest radiographs
for the diagnosis of pneumonia in children) [10].
Randomization
Random numbers were computer generated, by using
variable length permuted blocks at the coordinating site
using STATA 10 program. A separate list was generated
for each site and the individual patient assignments were
placed in a series of sealed opaque envelopes that were
opened for serially eligible patients. The eligible study
participants were randomly allocated to either the hos-
pital group in which syrup amoxicillin (50 mg/kg/d in
two divided doses) was administered in hospital for ini-
tial two days by hospital staff followed by administration
at home for five days by the care-giver, or, to the home
group in which the first dose of amoxicillin was adminis-
tered in hospital and subsequent doses were adminis-
tered by the care-giver at home for seven days.
Data collection
Clinical and demographic data was collected at baseline
along with throat swab and nasopharyngeal aspirate.
Both groups were followed up through home visits on
day 3, 5, 8 & 14 and home group had an additional
home visit at 24 h. During these follow-up home visits,
data regarding outcomes were collected. This included
clinical deterioration of disease any time after enrolment,
change of antibiotics, hospitalization, serious adverse
Table 1 Exclusion Criteria
1. Known or clinically recognizable chronic conditions
2. History of > 2 weeks of cough /difficulty in breathing
3. Past history of more than 3 wheezing episodes or physician
diagnosed asthma
4. LCI that responds to trial of nebulization
5. Respiratory rate (RR) >70 breaths per minute in calm child
6. Known HIV positive child or HIV status of mother known to be
positive and status of child not known/defined.
7. Hospitalization for > 48 h in the last two weeks
8. Measles in the last month
9. Clinically severe malnutrition (weight for length < −3 SD or
kwashiorkor) (refer to WHO growth chart)
10. Rickets
11. Central cyanosis
12. Kerosene poisoning within last 48 h
13. Oxygen saturation (pulse oximetry) <88 % on room air
14. Abnormally sleepy or difficult to wake
15. Inability to drink
16. Stridor in calm child
17. Convulsions during this illness
18. Known any antibiotic therapy for 48 h or more immediately prior to
admission
19. Other diseases requiring antibiotic therapy, e.g. Meningitis,
tuberculosis, dysentery, etc.
20. Persistent vomiting (>3 episodes of vomiting within 1 h)
21. Grunting
22. Known prior anaphylactic reaction to penicillin or amoxycillin
23. Severe dehydration according to WHO guidelines
24. Severe pallor
25. Suspected surgical pathology
26. Living out of the follow-up area of the study (30 kms)
27. Subject previously included in the same trial or already included in
another ongoing trial anywhere
28. Presence of radiological consolidation / effusion / pneumothorax
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events considered related to amoxicillin, left against
medical advice (LAMA), voluntary withdrawal of con-
sent, or loss to follow up.
Clinical outcomes
Treatment failure was defined as presence of any one of
the following conditions - clinical deterioration of dis-
ease any time after enrolment that required change of
antibiotics, hospitalization (any time for the children in
the home managed group or clinical decision to extend
the hospitalization longer than 48 h in the hospitalized
group), an occurrence of a serious adverse event related
to amoxicillin, left against medical advice (LAMA), vol-
untary withdrawal of consent from the study, or loss to
follow up. Clinical deterioration was defined as appear-
ance of signs of very severe disease such as persistent
vomiting (vomiting repeated three times within an hour
due to any reason), central cyanosis, grunt, stridor, ab-
normal sleepiness or difficulty to wake, inability to drink,
SpO2 < 85 %, convulsions, or death [6]. Antibiotics
would be changed if there was clinical deterioration, de-
veloping a co-morbid condition, or, persisting fever >
98.6 °F with lower chest indrawing even after 3rd day, or,
fever alone at day 5, or, lower chest indrawing alone
(non responsive to three doses of nebulisation with
bronchodilator) at day 5 (as reported by the mother), or,
persistence of fast breathing after day 7 which is unre-
sponsive to three doses of nebulization with broncho-
dilator. Rigorous training and retraining of the research
physicians using standard operating procedures was used
to minimize the biases that may arise due to lack of uni-
formity in assessing clinical signs between treatment
groups and across sites. Strong quality monitoring pro-
cesses were also established. An additional file describes
the relevant standard operating procedures in details
[see Additional file 1].
Cost outcomes
Cost data were collected for 17.2 % patients starting
from before enrolment till day 14 or till the patient re-
covered whichever was earlier. Three distinct types of
forms were used at enrolment, daily in the hospital and
at each visit respectively. The cost data were also col-
lected for those patients who left against medical advice.
The forms included information about the service pro-
vider and the type of service. We disregarded fixed costs
that were common for the two strategies. The protocol
driven costs, such as investigations required for the
study but not otherwise conducted routinely, were ex-
cluded from calculation of these costs. The variable
costs i.e. direct medical, direct non-medical and indirect
costs of the two treatment arms were measured using
micro-costing technique [11].
Direct medical costs included costs of medical re-
sources utilized by the patient at the out-patient and
during hospital stay as calculated from the patient's per-
spective eg cost of medications, physician and nurses
services and other paramedical services, bed cost, and
the laboratory investigations.
Direct non-medical costs included the cost of travel-
ling to the hospital for the patient and the family, cost of
food to the family and patient during hospitalization and
other incidental cost to the family attributed to the
illness.
Indirect costs were measured by the lost wages for
employed parents or guardians attending to the
participant.
The median differences in costs and the predictors of
total cost were analyzed as cost data was not normally
distributed. The incremental cost-effectiveness of the
two treatment strategies was also assessed.
Sample size
Sample size estimates were based to detect equivalence
and on the hypothesis that children who were treated
with oral amoxicillin at home would experience a failure
rate of 15 %, and, would be within 5 % of those treated
for first 48 h in hospital. The estimated sample size was
1,234 i.e. 617 per group. The sample size was calculated
for the clinical trial but provided 90 % power for a two-
tailed alternative hypothesis to calculate a mean differ-
ence in costs between the two interventions.
Statistical analysis
Baseline characteristics of the two treatment groups
were compared using chi-square tests for categorical
variables and ANOVA for continuous variables. We con-
ducted the analysis using both intention to treat (ana-
lyzed as randomized) and per protocol analysis (included
all clinical causes of treatment failure, but excluded
treatment failure due to lost to follow up, LAMA, and
voluntary withdrawal from the study). Cox proportional
hazards models were used to estimate the relative haz-
ards (RH) of treatment failure in the two groups up to
14 days and to explore associations between the same
baseline explanatory covariates (age, feeding status,
immunization, antibiotics prior to 48 h, weight for age Z
scores, body temperature, respiratory rates, oxygen sat-
uration, auscultatory wheeze, crackles, radiological infil-
trates, number of rooms in the house and type of fuel
used for cooking) and outcome. We used forward step
wise method and identified explanatory candidate vari-
ables (p ≤ 0.1) for inclusion in adjusted models as plaus-
ible predictors of treatment failure. The Kaplan-Meier
curves for the cumulative probability of treatment suc-
cess were also plotted for the two groups and the overall
difference in their rates of treatment success was
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examined using the log-rank test. Statistical analysis was
conducted using STATA 10 data analysis software.
Economic analysis
The medians of the direct medical, direct non-medical
and indirect costs and their inter-quartile ranges were
calculated. Group differences in median costs of the
treatment strategies were assessed using the median test.
Univariate analysis was conducted for the predictors of
cost variation, such as data on patient demographic
characteristics, clinical history, length of stay and other
utilization of resources for treatment of this episode of
pneumonia before entry of patients into the trial. Multi-
variable regression analysis (OLS, with log transform-
ation) was also used to predict total costs across the cost
categories using pre-randomization variables, the alter-
nate treatment strategies and other covariates that relate
to resource consumption. Differences were considered
statistically significant if they had a two-tailed p value
less than 0.05. The hypothesis, that home treatment is
more cost-effective than hospital treatment, was also
tested by comparing the cost-effectiveness ratios. The in-
cremental cost-effectiveness was estimated as the differ-
ence in the predicted total costs in the numerator and
the difference in effects i.e. the number of patients cured
(1-treatment failure) or the number of cases of treat-
ment failure avoided in the denominator.
Results
The study was conducted from October 2008 to March
2011. Of the children screened for WHO defined severe
pneumonia, 1118 (16.9 %) were enrolled, 554 were
assigned to home treatment, and 564 were assigned to
hospital treatment, across six sites in India (Fig. 1). The
number of children enrolled from different sites were
377 (33.7 %), 328 (29.3 %), 316 (28.3 %), 50 (4.5 %), 37
(3.3 %), and 10 (0.9 %) from Chandigarh, Chennai, Nag-
pur, Sewagram, Aligarh, and Pune respectively. The
1118 participants
randomised
564 allocated to hospital
group. All analysed
554 allocated to home
group. All analysed
540 improved.
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Fig. 1 Trial profile
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reasons for excluding 83.1 % of screened children are
shown in Table 2. The two intervention groups were not
statistically different in their baseline characteristics
(Table 3).
Clinical outcomes
The cumulative overall treatment failure (home + hos-
pital) on oral amoxicillin at different time points were
6.8 % at <72 h, 11.2 % at <5 days, 12.5 % at <7 days,
and 14.5 % at <14 days by intention to treat and 4 %
at <72 h, 8.4 % at <5 days, 9.6 % at <7 days, and
11.5 % at <14 days respectively by per protocol
analysis.
The treatment failure rate at 14 days in hospital group
was 18.1 % (102/564) as compared to 10.8 % (60/554) in
the home group. There were 30 (5.4 %) failures due to
clinical deterioration (presence of any one of these con-
ditions - persistent vomiting, central cyanosis, grunt,
stridor, abnormally sleepy or difficult to wake, inability
to drink, or convulsions) in the home group and 42
(7.4 %) in the hospital group (Fig. 1) which was not sig-
nificantly different. The failures due to LAMA or volun-
tary withdrawal were significantly more in hospital
group as compared the home group. [5.3 % (30/564)
vs 0.5 % (3/554); p < 0.001] Kaplan Meier curves for
differences between treatment successes in the home




Enrolled (%) 1,118 16.9
Inclusion criteria not satisfied
Not satisfying Age 3–59 months 462 5.1
Had no lower chest indrawing on examination 1489 16.3
Caretaker is not willing to sign informed consent form 4060 44.5
Exclusion criteria, number (%)
Known or clinically recognizable chronic conditions 224 2.5
History of >2 weeks of cough / difficulty in breathing 195 2.1
Past history of more than 3 wheezing episodes or physician diagnosed asthma 267 2.9
LCI that responds to trial of nebulization 743 8.1
Known HIV positive child. HIV status of mother known to be positive & of child not known/defined 16 0.2
Hospitalization for > 48 h in the last two weeks 127 1.4
Measles in the last month 64 0.7
Clinically severe malnutrition (weight for length < −3 SD or kwashiorkar) 163 1.8
Rickets 21 0.2
Kerosene poisoning within last 48 h. 17 0.2
Antibiotic therapy for 48 h or more immediately prior to admission 431 4.7
Other diseases requiring antibiotic therapy, e.g. Meningitis, tuberculosis, dysentery, etc. 28 0.3
Known prior anaphylactic reaction to penicillin or amoxycillin 8 0.1
Severe dehydration according to WHO guidelines 12 0.1
Severe pallor 19 0.2
Suspected surgical pathology 12 0.1
Living out of the follow-up area of the study (30 kms) 308 3.4
Subject previously included in the same trial or already included in another ongoing trials anywhere. 44 0.5
Presence of danger sign c before radiology evaluation 358 3.9
Presence of danger sign after radiology evaluation 9 0.1
Presence of radiological consolidation/ effusion / pneumothorax 45 0.5
Total reasons for exclusionb 9122
aProportion for the presence of exclusion criteria. The denominator is total reasons for exclusion2s
bA child could have more than one reason for exclusions
cDanger signs are presence of any one clinical condition - abnormally sleepy or difficult to wake, persistent vomiting, inability to drink, grunting, stridor, central
cyanosis, convulsions, RR > 70 breaths per minute, Sp02 < 88 % on room air
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and hospital group with log rank tests for the
intention to treat (ITT) analysis showed that the hos-
pital group was significantly more likely than home
children to fail treatment at any time point. (HR 1.79;
95 % C.I. 1.30, 2.46, p < 0.01) (Fig. 2) The per proto-
col analysis, though tended to show a similar trend
(RR 1.32), was statistically non-significant (p = 0.10).
The Cox Regression model showed that infants (3–11
months) and patients who had antibiotics within 48 h
of enrolment had a higher likelihood of failing treat-
ment at any point from enrolment to 14 days (per
protocol and intention to treat analysis). Additionally,
belonging to the hospital group and residence in
homes with high polluting fuels were significantly as-
sociated with treatment failure in ITT, because chil-
dren in the hospital group were more likely to fail
treatment at any time than children in the home
group (with LAMA accounting for the majority of
these failures) (Table 4).
Two children died within the first 72 h, one in the
home group, and the other in the hospital group. There
were no other serious adverse events. Neither of the
deaths were considered to be related to the study treat-
ment with oral amoxicillin.
Table 3 Baseline Characteristics in Home and Hospitalized Children
Baseline characteristic Home (N = 554) Hospital (N = 564)
n % n %
Sex (Female) 207 37.4 204 36.2
Infants (3–11 months old) 237 42.8 277 49.1
Children (12–23 months old) 164 29.6 138 24.5
Children (24–59 months old) 153 27.6 149 26.4
Breast feeding indicators(3-59months)
Exclusive breast feeding 361 65.2 373 66.1
Bottle feeding 231 41.7 209 37.1
Timely complementary feeding 431 77.8 443 78.6
Immunization status up-to-date 516 93.1 510 90.4
Report of antibiotics in < 48 h prior to enrollment 56 10.1 59 10.5
Weight-for-age Z score (mean ± sd) 554 −1.5 ± 1.3 564 −1.6 ± 1.3
Weight-for-age Z score (<−2) 197 35.6 205 36.4
Length/ height (cm)(mean ± sd) 548 75.9 ± 11.7 560 74.7 ± 12.1
Temperature (°F)(mean ± sd) 554 99.5 ± 1.5 564 99.6 ± 1.5
Respiratory rate per min (mean ± sd)
Infants 237 47.3 ± 8.9 277 48.9 ± 8.7
Children 317 43.0 ± 9.1 287 43.9 ± 9.8
Auscultatory wheeze
Infants 140/237 59.1 176/277 63.5
Children 155/317 48.9 121/287 42.2
Crackles
Infants 174/237 73.4 211/277 76.2
Children 243/317 76.7 228/287 79.4
Pulse oximetry (mean ± sd)
Infants 236 96.1 ± 2.9 277 95.9 ± 3.2
Children 317 95.9 ± 3.0 286 95.8 ± 3.1
Any Infiltrates in chest x-ray 322/530 60.8 365/540 67.6
No. of rooms in house (mean ± sd) 554 2.4 ± 1.4 564 2.3 ± 1.4
Fuel used for cooking
Low polluting fuel 220/553 39.8 249/556 44.8
High polluting fuel 333/553 60.2 307/556 55.2
Any smoker who smokes in the house 121 21.8 129 22.9
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Cost outcomes
The average cost of treating a child at a government
hospital in India with subsidized rates was Rs. 567 when
patients were hospitalized for only two days. The median
total cost for treating at home was significantly less than
treating at hospital for the first 48 h. (Rs 399 for home
vs. Rs 602 for the hospital group, p < 0.001) (Table 5)
The predictors of total mean costs of treatment are
shown in Table 6. The patient characteristics associated
with higher costs of treatment were age 3–11 months,
higher temperature, lower pulse oximetry readings, and
presence of auscultatory wheeze. The boot strap cost es-
timates of Rs.702 (95 % CI 701, 703) for the hospital
group and Rs. 427 (95 % CI 427, 428) for the home
group were consistent with those determined by the
above regression and were significantly higher for the
hospital group (p < 0.001). Figure 3 shows the plotting of
the boot strap estimates (20,000 re-samples) on the cost
effectiveness plane. It indicates that it is cheaper to be
treated at home (all points are below zero in the Y co-
ordinate of costs) with identical effects (all points are
equally distributed on either side of zero in the X co-
ordinate of effectiveness).
Discussion
Is oral Amoxicillin effective?
Our study showed that oral amoxicillin, whether admin-
istered at hospital or at home for the first 48 h was ef-
fective in treating WHO defined severe pneumonia in
93.2 % of eligible patients who were otherwise clinically
stable and did not have co-morbid conditions. Although
the rates of clinical deterioration were similar over the
14 day follow up, the treatment failure rate was more in
the hospital group (18.1 % vs 10.8 %), due to higher rates
of LAMA/voluntary withdrawal (5.3 % in hospital group
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Fig. 2 Kaplan Meier Curves for treatment success rates for intention
to treat analysis
Table 4 Cox Regression Analysis for Treatment Failure Using the Per Protocol and Intention to Treat Analysis up to 14 days
Characteristic Per-protocol analysis Intention to treat analysis
Hazard ratio 95 % CI p-value Hazard ratio 95 % CI p-value
Treatment group
Home 1.00 1.00
Hospital 1.32 0.93 1.88 0.12 1.61 1.16 2.24 0.00
Age group
Infants (3–11 months old) 1.00 1.00
Children (12–59 months old) 0.65 0.45 0.93 0.02 0.69 0.49 0.96 0.03
Exclusive breast feeding
No 1.00 1.00
Yes 1.52 0.98 2.36 0.06 1.46 0.99 2.16 0.06
Antibiotics prior to enrollment
No 1.00 1.00
Yes 1.79 1.06 3.02 0.03 1.72 1.07 2.76 0.02
Fuel used for cooking
Low polluting fuel 1.00 1.00
High polluting fuel 1.43 0.98 2.10 0.06 1.51 1.06 2.15 0.02
Study Site
Chandigarh 1.00 1.00
Chennai 0.18 0.09 0.33 0.00 0.41 0.26 0.64 0.00
Nagpur 0.58 0.38 0.91 0.02 0.63 0.42 0.96 0.03
Pune 2.33 0.84 6.48 0.11 2.78 1.11 6.97 0.03
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composite outcome “treatment failure”. This was a con-
servative estimate of treatment success as there is uncer-
tainty of the clinical outcome and treatment adherence
in those who leave the study prematurely. Figure 1 de-
scribes frequency of presence of various criteria for
treatment failure and of true clinical deterioration. Sec-
ondly, children who are hospitalized are closely moni-
tored by skilled research staff for presence of signs of
clinical deterioration and are also likely to experience a
change in antibiotic (also a criterion for treatment fail-
ure) by a treating physician. These could have potentially
increased the failure rate in the hospital group. However,
clinical deterioration at < 7 days was not significantly dif-
ferent between the groups indicating that it did not
cause a potential bias in this study. Selective
randomization of sicker children to the hospital was un-
likely as the allocation was concealed. The high rate of
LAMA in the hospital group (5.1 %) demonstrates that
hospitalization is a barrier to children receiving a full
course of treatment and perhaps the caregivers prefer to
have their children who otherwise do not have co-
morbid conditions such as those listed out in the Table 1,
treated at home.
The baseline characteristics predictive of treatment
failure were known risk factors such as younger age 3–
11 months [12, 13], those who received antibiotics less
than 48 h prior to enrollment (perhaps clinically sicker
children) and use of solid fuels for household cooking, a
known risk factor for poor treatment response [14–18].
Also, all other sites had lower failure rates than Chandi-
garh. This was mostly because of persistence of LCI at
48 h contributed mostly by children of hyperreactive air-
way disease. National Family Health Survey 2005–06 has
reported the northern states to have higher prevalence
and symptoms of acute respiratory infections [3]. Chan-
digarh is in the northern states of India and has colder
winters than the remaining sites and reports higher inci-
dence of hyperreactive airway disease. Also, Chandigarh
site was a referral tertiary care hospital with larger pa-
tient load.
Table 5 Treatment costs in different cost categories in the home and hospital group
Type of costs Home Hospital P-
value*n (median ± IQR) n (median ± IQR)
Cost of outpatient visits
Direct Medical Cost 94 104 ± 213 97 83 ± 215 0.6
Direct Non Medical cost 94 57.5 ± 68 97 60 ± 85 0.7
Indirect Cost 86 0 ± 0 84 0 ± 0 0.5
Hospital Cost
Direct Medical Cost 76 130 ± 36 95 166 ± 101 <0.001
Direct Non Medical cost 76 40 ± 37 95 165 ± 130 <0.001
Indirect Cost 76 0 ± 50 95 0 ± 150 0.02
Total Direct Medical Cost 94 208 ± 204 97 215 ± 236 0.09
Total Direct Non Medical cost 94 90 ± 91 97 225 ± 210 <0.001
Total Indirect Cost 94 0 ± 100 97 0 ± 150 0.1
Total Cost 94 399 ± 346 97 602 ± 524 <0.001
*P-value of median test
Table 6 Predictors of total mean costs for treating WHO
defined severe pneumonia
Variable β (95 % CI) P-value
Treatment group (Hospital) 239.8 (102.6, 377.0) 0.00
Age group (12–59 months old) −195.7 (−341.6, −49.9) 0.01
Antibiotics prior to enrollment −22.7 (−297.5, 252.1) 0.87
Weight for age Z-score −36.4 (−94.0, 21.2) 0.21
Temperature 28.1 (3.9, 52.2) 0.02
Respiratory rate per min 1.9 (−6.1, 10.0) 0.64
Pulse oximetry −26.9 (−50.4, −3.4) 0.03
Auscultatory wheeze 204.8 (59.5, 350.1) 0.01
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A recent systematic review has reported results of 4
trials, (2 multi-centric hospital based studies and 2 com-
munity based cluster trials) [19]. They reported non in-
feriority of Oral amoxicillin administered either in
hospital or community for treatment of severe pneumo-
nia as compared to standard treatment by injectable
penicillin. The two community based cluster trials com-
pared oral amoxicillin administered at home by commu-
nity health workers to administration of cotrimoxazole
in the community followed by standard of care of receiv-
ing parenteral therapy at hospital. The hospital based
studies compared the use of oral amoxicillin for manage-
ment of WHO defined severe pneumonia to either in-
jectable penicillin or ampicillin for 48 h. None of these
studies compared the use of oral amoxicillin adminis-
tered for the first 48 h under hospital supervision to am-
bulatory management at home with oral amoxicillin.
This is the only study that not only reports the overall
response of severe pneumonia to oral amoxicillin
whether administered at home or hospital but also pro-
vides the cost effectiveness of the treatment.
Is oral Amoxicillin cost effective?
The total cost of treating severe pneumonia in hospital
for the first 48 h was significantly more than being
treated at home. There were no significant differences
between the two groups in costs of outpatient visits, but
significantly higher costs were observed in the hospital
group for the costs of hospitalization and for non-
medical costs, which includes expenditure of the care-
giver on travel or meal costs when taking care of the
child. This was despite the fact that cost of
hospitalization was perhaps an underestimate of the true
costs as only variable costs were measured, and, because
the costs of treatment and hospitalization are subsidized
at Indian government hospitals. These results thus sug-
gest that it will be cost efficient to manage children with
WHO defined severe pneumonia at home with oral
amoxicillin.
This is an important finding because WHO has rec-
ommended that children with severe pneumonia must
be hospitalised which increases the cost of treatment
due to daily bed charge, cost of services of medical
personnel, cost of medications, monitoring, lost
wages, cost of food for caretakers etc. If the treatment
at home for a subgroup of severe pneumonia patients
without high risk features, is as effective as treating
in the hospital then it will be cost effective to recom-
mend treatment guidelines for management of severe
pneumonia at home.
Can these results be generalized?
Exclusion of children with additional risk factors such as
measles, severe malnutrition, and those with radiological
consolidation could apparently limit the external validity
of the results. However, these were uncommon reasons
for exclusion as most seriously ill children with presence
of danger signs would be immediately admitted to hos-
pital and would not undergo the screening process. Of
the 6634 patients of severe pneumonia that presented to
the 6 tertiary care hospitals, only 16.9 % were eligible to
participate to receive oral amoxicillin. The most com-
mon reason for exclusion in this study at screening was
refusal of consent to participate if the child were to be
randomized to hospital group. This trend was also ob-
served after the randomization to hospital group when a
large number of children left against medical advice and
were declared treatment failure by definition despite no
clinical deterioration. The other reasons for exclusion
were wheeze or lower chest indrawing responding to
nebulization (11 %) or having received an antibiotic for
longer than 48 h (4.7 %). Thus, since children with co-
morbid conditions were not included in the trial these
results are largely generalizable to patients with severe
pneumonia who don’t have co-morbidities or danger
signs.
Limitations and strengths
Excluding patients with consolidation could also exclude
those with bacterial pneumonia, while those children
with fever, wheeze and infiltrates are more likely to be of
nonbacterial causes or viral pneumonias.
Children with allergic bronchitis, asthma, bronchiolitis
and viral pneumonia can also manifest with clinical signs
of WHO defined severe pneumonia of cough with LCI.
Excluding children whose LCI disappeared after nebuli-
zation with bronchodilators or those with a past history
of wheeze or bronchodilators administration ensured
that we minimize inclusion of children with allergic
bronchitis or asthma. In developing countries, mixed
viral and bacterial infections are not uncommon, and
hence need to be treated with antibiotics. However, ad-
mitting these children as severe pneumonia will be an
additional cost for the Government and for the patient’s
family.
The limitation in recording the cost data was that it was
based partially on recall and partially on documents. It was
also difficult to collect the cost data from patients who left
against medical advice and those who had treatment failure.
The sample size calculation was based on the clinical out-
comes and not for the economic analysis. This may have in-
fluenced the validity of the cost effectiveness analysis.
Lastly, multiplicity of end points or a composite of
end points of treatment failure that includes many con-
ditions such as clinical deterioration, hospitalization, devel-
opment of co-morbid conditions, changing antibiotics etc.
do provide statistical efficiency but at the risk of difficulties
with interpretation. Similarly, including treatment failures
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due to leaving against medical advice, lost to follow up or
voluntary withdrawal can overestimate treatment failures
and may not indicate true clinical deterioration, again caus-
ing difficulties with interpretation. Therefore, we analyzed
treatment failure on intention to treat as well as per proto-
col basis.
Finally, this is the only trial that has evaluated the cost
effectiveness and efficacy of oral amoxicillin adminis-
tered at the hospital for first 48 h as compared to home
administered oral amoxicillin to complete a course of
7 day treatment of WHO defined severe pneumonia in
children at tertiary care hospitals as it not only reports
the overall response of severe pneumonia to oral amoxi-
cillin whether administered at home or hospital but also
provides the costs of treatment and the differences in
cost in the hospitalized and home group. This is an im-
portant strength of the study and will help greatly to
guide policy for the case management of severe pneu-
monia in the developing countries.
Conclusions
The study results suggest that in selected children aged 3–
59 months with chest indrawing pneumonia and without
any of the study exclusion criteria, home based treatment
of with oral amoxicillin is equivalent to 48 h of hospital ad-
ministered oral amoxicillin followed by home based treat-
ment. However, the results of this study should be
generalized with due consideration of the fact that the se-
lected participants had a limited spectrum of presentation
which may not be true in the real life scenario.
This study also concludes that cost of treatment of severe
pneumonia with oral amoxicillin in the hospital for initial
48 h followed by continuing it at home for 5 days is signifi-
cantly more than the cost of treatment with oral amoxicillin
at home for 7 days.
Hence, consistent with the recent WHO simplified
guidelines, it will be cost effective to manage select
stable children with only fast breathing and chest-
indrawing or WHO defined chest indrawing pneumonia
at home with oral amoxicillin.
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